Dermata Therapeutics Directors Boost Stakes in Quiet Stock‑Option Surge, Betting on Next Phase of Clinical Pipeline
Dermata insiders’ option purchases signal confidence, but the next earnings report will decide if the biotech’s stock can rally beyond its current volatility.
2 minutes to read